Phaseline

Companies › CASI pharmaceuticals

CASI pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CID-103
anti-CD38 monoclonal antibody
CD38Phase 1Chronic Immune Thrombocytopenia; Antibody Mediated RejectionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07017725CID-103Phase 1Chronic Immune ThrombocytopeniaHematologyDec 2026
NCT07641426CID-103Phase 1Antibody Mediated RejectionOtherMay 2030

From the company's SEC filings

Cash of $6m on 2025-12-31; operating cash outflow about $21m a year; runway about 3 months at that burn, to Apr 2026

Private offerings reported to the SEC (Form D)

Targets

CD38 (1)

Companies with the same targets

Takeda Johnson & Johnson (Janssen) Zhejiang ACEA Pharmaceutical Biogen Sanofi Celltrion GSK Sinocelltech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.